News headlines about Cytokinetics (NASDAQ:CYTK) have trended somewhat positive on Friday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cytokinetics earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 47.2613287424211 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

A number of equities analysts have recently issued reports on CYTK shares. Needham & Company LLC lowered shares of Cytokinetics from a “strong-buy” rating to a “buy” rating and lowered their target price for the stock from $22.00 to $12.00 in a research report on Tuesday, November 21st. HC Wainwright lowered their target price on shares of Cytokinetics from $26.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, November 21st. Cowen restated a “buy” rating and set a $11.00 target price on shares of Cytokinetics in a research report on Tuesday, February 20th. Cantor Fitzgerald set a $10.00 target price on shares of Cytokinetics and gave the stock a “hold” rating in a research report on Monday, February 12th. Finally, JMP Securities restated an “outperform” rating and set a $13.00 target price (down from $17.00) on shares of Cytokinetics in a research report on Tuesday, November 21st. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $16.60.

How to Become a New Pot Stock Millionaire

Cytokinetics (NASDAQ:CYTK) opened at $8.30 on Friday. Cytokinetics has a 1 year low of $7.00 and a 1 year high of $17.20. The company has a quick ratio of 8.46, a current ratio of 8.46 and a debt-to-equity ratio of 0.29.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.04). Cytokinetics had a negative net margin of 172.27% and a negative return on equity of 96.95%. The firm had revenue of ($0.02) million during the quarter, compared to analysts’ expectations of $4.83 million. equities research analysts forecast that Cytokinetics will post -1.81 EPS for the current year.

WARNING: This piece was reported by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at

Cytokinetics Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with's FREE daily email newsletter.